What’s with All the Bio M&A in 2019?: A Quick Take

Nate Chang, Kouki Harasaki, and Frank Chen

M&A in the biotech industry is off to a fast start in 2019. Just this past weekend, Roche announced it is acquiring Spark Therapeutics; Ipsen announced its acquisition of Clementia Pharma; and GE announced a spinoff of its biopharma business to Danaher.

Is this all just coincidence… or are there bigger trends at play? In this a16z hallway-style quick-take on recent news, a16z partners Kouki Harasaki (in bio go-to-market) and Nate Chang (in bio corporate development) chat with a16z operating partner Frank Chen about why all this M&A activity is happening now, and what it means for the bio startup ecosystem overall.

watch time: 21 minutes

Want more a16z Bio + Health?

Sign up for our bio + health newsletter to get the latest take from us on the future of biology, technology, and care delivery.

Thanks for signing up for the a16z Bio + Health newsletter.

Check your inbox for a welcome note.

MANAGE MY SUBSCRIPTIONS By clicking the Subscribe button, you agree to the Privacy Policy.
go to top